Adial Pharmaceuticals Inc (ADIL) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1180 SEMINOLE TRAIL CHARLOTTESVILLE, VA 22901 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,751 | 2,827 | 4,002 | 6,062 | 4,401 | 6,777 | |||
| Cash and cash equivalent | 3,751 | 2,827 | 4,002 | 6,062 | 4,401 | 6,777 | |||
| Prepaid expense | 429 | 10 | 233 | 831 | |||||
| Intangible current assets | 1 | 1 | |||||||
| Other undisclosed current assets | 308 | 372 | 349 | 390 | 501 | 64 | |||
| Total current assets: | 4,059 | 3,199 | 4,780 | 6,462 | 5,136 | 7,673 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 194 | 246 | |||||||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 50 | 58 | |||||||
| Long-term investments and receivables | 982 | 1,534 | |||||||
| Long-term investments | 982 | 1,534 | |||||||
| Intangible asset, including goodwill, after accumulated amortization | 3 | 4 | 253 | 254 | 6 | ||||
| Goodwill | 249 | 249 | |||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 3 | 4 | 4 | 5 | 6 | ||||
| Other noncurrent assets | 6 | ||||||||
| Other undisclosed noncurrent assets | 455 | 455 | 350 | ||||||
| Total noncurrent assets: | 985 | 1,538 | 953 | 1,013 | 356 | 6 | |||
| TOTAL ASSETS: | 5,044 | 4,737 | 5,733 | 7,475 | 5,491 | 7,680 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 928 | 581 | 1,549 | 2,663 | 1,505 | 539 | |||
| Accounts payable | 250 | 103 | 394 | 286 | 649 | 190 | |||
| Accrued liabilities | 677 | 478 | 1,155 | 2,377 | 857 | 349 | |||
| Debt | 57 | 50 | |||||||
| Other liabilities | 10 | 10 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | 175 | |||||
| Other undisclosed current liabilities | 48 | 72 | |||||||
| Total current liabilities: | 976 | 653 | 1,791 | 2,722 | 1,505 | 539 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 207 | ||||||||
| Liabilities, other than long-term debt | 173 | 23 | |||||||
| Deferred income tax liabilities | 23 | 23 | |||||||
| Operating lease, liability | 151 | 207 | |||||||
| Other undisclosed noncurrent liabilities | 492 | 1,014 | |||||||
| Total noncurrent liabilities: | 665 | 1,245 | |||||||
| Total liabilities: | 976 | 653 | 2,456 | 3,967 | 1,505 | 539 | |||
| Equity | |||||||||
| Equity, attributable to parent | 4,068 | 4,084 | 3,276 | 3,508 | 3,986 | 7,141 | |||
| Common stock | 6 | 2 | 27 | 21 | 14 | 10 | |||
| Additional paid in capital | 86,057 | 72,880 | 66,924 | 54,430 | 35,491 | 27,757 | |||
| Accumulated deficit | (81,995) | (68,798) | (63,675) | (50,943) | (31,520) | (20,627) | |||
| Total equity: | 4,068 | 4,084 | 3,276 | 3,508 | 3,986 | 7,141 | |||
| TOTAL LIABILITIES AND EQUITY: | 5,044 | 4,737 | 5,733 | 7,475 | 5,491 | 7,680 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 46 | 376 | ||||||
| Other operating income | 376 | |||||||
| Other income | 46 | |||||||
| Cost of revenue (Deferred Sales Inducement Cost, Amortization Expense) | (4,464) | |||||||
| Gross profit: | (4,464) | 46 | 376 | |||||
| Operating expenses | (8,284) | (6,888) | (13,317) | (19,289) | (10,928) | (8,245) | ||
| Other undisclosed operating income (loss) | 4,464 | (46) | (376) | |||||
| Operating loss: | (8,284) | (6,888) | (13,317) | (19,289) | (10,928) | (8,245) | ||
| Nonoperating income (expense) | (4,913) | (114) | 585 | (229) | 35 | (347) | ||
| Investment income, nonoperating | 179 | 70 | 585 | (275) | 32 | 95 | ||
| Other nonoperating income (expense) | (75) | 10 | 3 | |||||
| Loss from continuing operations before income taxes: | (13,197) | (7,002) | (12,732) | (19,517) | (10,893) | (8,591) | ||
| Income tax expense (benefit) | 1 | 94 | 446 | (14,246) | ||||
| Loss from continuing operations: | (13,197) | (7,002) | (12,731) | (19,423) | (10,447) | (22,838) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (19,423) | (10,447) | (22,838) | |
| Income from discontinued operations | 1,879 | |||||||
| Other undisclosed net income (loss) | (446) | 14,246 | ||||||
| Net loss available to common stockholders, diluted: | (13,197) | (5,123) | (12,731) | (19,423) | (10,893) | (8,591) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (13,197) | (5,123) | (12,731) | (19,423) | (10,893) | (8,591) | ||
| Comprehensive loss, net of tax, attributable to parent: | (13,197) | (5,123) | (12,731) | (19,423) | (10,893) | (8,591) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.